Storia in 3 fonti

GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - GSK (NYSE:GSK)

GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration with Alector.

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo9 h fa

GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration with Alector.

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.